PDCD4 and plasma cell myeloma: However, in both CLL and B-lymphoma cells, anti-IgM-induced PDCD4 down-regulation was due to increased proteasomal degradation as it was reversed by PSI, including bortezomib which is used to treat multiple myeloma and mantle cell lymphoma.